Scemblix Approved for Ph+ Chronic Myeloid Leukemia in Chronic Phase
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).